Lin Liu1, Lin Chen1, Xuan Wu2, Xiang Li2, Yang Song3, Qian Mei2, Jing Nie4, Weidong Han5. 1. Department of General Surgery, PLA General Hospital, Beijing, 100853, China. 2. Department of Immunology, Institute of Basic Medicine, PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. 3. Department of Microbiology, PLA General Hospital, Beijing, 100853, China. 4. Department of Immunology, Institute of Basic Medicine, PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. nnjj2002@163.com. 5. Department of Immunology, Institute of Basic Medicine, PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China. hanwdrsw69@yahoo.com.
Abstract
PURPOSE: The DNA-demethylating agent decitabine has shown clinical response for the treatment of hematological malignancies and solid tumors, while the mechanisms underlying its antitumor capacity are not fully understood. METHODS: The sensitivities of cancer cells to different chemotherapeutic drugs, such as cisplatin, paclitaxel, and 5-FU, were detected. The tumor sphere formation assay was used to evaluate the effects of low-dose decitabine on cancer-initiating stem cells. RESULTS: We observed that the chemotherapy sensitivity of various cancer cells was enhanced following non-toxic low-dose decitabine treatment. Moreover, low-dose decitabine treatment suppressed the self-renewal of cancer-initiating cells and inhibited the expression of pluripotency markers. Strikingly, low-dose decitabine was able to augment chemosensitivity in cancer stem cells, likely by the upregulation of miRNA-497, which was reported to be downregulated and to have promoted cell apoptosis in multiple cancers. CONCLUSIONS: These results indicated that the DNA-demethylating agent could target cancer stem cells and reverse their chemotherapeutic resistance by regulating the endogenous expression of microRNAs.
PURPOSE: The DNA-demethylating agent decitabine has shown clinical response for the treatment of hematological malignancies and solid tumors, while the mechanisms underlying its antitumor capacity are not fully understood. METHODS: The sensitivities of cancer cells to different chemotherapeutic drugs, such as cisplatin, paclitaxel, and 5-FU, were detected. The tumor sphere formation assay was used to evaluate the effects of low-dose decitabine on cancer-initiating stem cells. RESULTS: We observed that the chemotherapy sensitivity of various cancer cells was enhanced following non-toxic low-dose decitabine treatment. Moreover, low-dose decitabine treatment suppressed the self-renewal of cancer-initiating cells and inhibited the expression of pluripotency markers. Strikingly, low-dose decitabine was able to augment chemosensitivity in cancer stem cells, likely by the upregulation of miRNA-497, which was reported to be downregulated and to have promoted cell apoptosis in multiple cancers. CONCLUSIONS: These results indicated that the DNA-demethylating agent could target cancer stem cells and reverse their chemotherapeutic resistance by regulating the endogenous expression of microRNAs.
Entities:
Keywords:
Cancer stem cell; Chemosensitivity; Decitabine; Epigenetic therapy; miRNA-497
Authors: Katherine B Chiappinelli; Pamela L Strissel; Alexis Desrichard; Huili Li; Christine Henke; Benjamin Akman; Alexander Hein; Neal S Rote; Leslie M Cope; Alexandra Snyder; Vladimir Makarov; Sadna Budhu; Sadna Buhu; Dennis J Slamon; Jedd D Wolchok; Drew M Pardoll; Matthias W Beckmann; Cynthia A Zahnow; Taha Merghoub; Taha Mergoub; Timothy A Chan; Stephen B Baylin; Reiner Strick Journal: Cell Date: 2015-08-27 Impact factor: 41.582
Authors: Hsing-Chen Tsai; Huili Li; Leander Van Neste; Yi Cai; Carine Robert; Feyruz V Rassool; James J Shin; Kirsten M Harbom; Robert Beaty; Emmanouil Pappou; James Harris; Ray-Whay Chiu Yen; Nita Ahuja; Malcolm V Brock; Vered Stearns; David Feller-Kopman; Lonny B Yarmus; Yi-Chun Lin; Alana L Welm; Jean-Pierre Issa; Il Minn; William Matsui; Yoon-Young Jang; Saul J Sharkis; Stephen B Baylin; Cynthia A Zahnow Journal: Cancer Cell Date: 2012-03-20 Impact factor: 31.743
Authors: Andrew C Little; Arvis Sulovari; Karamatullah Danyal; David E Heppner; David J Seward; Albert van der Vliet Journal: Free Radic Biol Med Date: 2017-05-31 Impact factor: 7.376
Authors: Yanina J L Jansen; Gontran Verset; Kelly Schats; Pieter-Jan Van Dam; Teofila Seremet; Mark Kockx; Jean-Luc B Van Laethem; Bart Neyns Journal: ESMO Open Date: 2019-03-05